Pancreatic Cancer Trial, Recruiting (NCT05334836)

Pancreatic Cancer Trial, Recruiting NCT05334836 Sponsor: Chinese University of Hong Kong Condition: Pancreatic Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05334836 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatic Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older
People who have at least one fluid-filled sac (cyst) in the pancreas, measuring 5mm or larger, that has been identified by a scan (CT, MRI, or endoscopic ultrasound) as a possible IPMN or MCN (specific types of pancreatic cysts) — or people who are generally healthy with no such condition
People who are able to give written agreement to take part and follow the study's procedures

Who may not be able to join:

People who are unable to give written consent to participate
People who have metal implants in their body or any other reason they cannot safely have an MRI scan
People who have health conditions that make it unsafe for them to undergo an endoscopy procedure
People who have been diagnosed with pancreatic cancer, or who have previously had surgery to remove part of the pancreas
People with high regular alcohol consumption — defined as more than 20g of alcohol per day (140g per week) for men, or more than 10g per day (70g per week) for women (confirm with trial site if unsure how this applies)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raymond S Tang, MD, Chinese University of Hong Kong

Phone: 26370428

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05334836

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Pancreatic Cancer

Trial contact: 26370428

More information: https://clinicaltrials.gov/study/NCT05334836

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older
People who have at least one fluid-filled sac (cyst) in the pancreas, measuring 5mm or larger, that has been identified by a scan (CT, MRI, or endoscopic ultrasound) as a possible IPMN or MCN (specific types of pancreatic cysts) — or people who are generally healthy with no such condition
People who are able to give written agreement to take part and follow the study's procedures

Who may not be able to join:

People who are unable to give written consent to participate
People who have metal implants in their body or any other reason they cannot safely have an MRI scan
People who have health conditions that make it unsafe for them to undergo an endoscopy procedure
People who have been diagnosed with pancreatic cancer, or who have previously had surgery to remove part of the pancreas
People with high regular alcohol consumption — defined as more than 20g of alcohol per day (140g per week) for men, or more than 10g per day (70g per week) for women (confirm with trial site if unsure how this applies)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

6 April 2022

Est. completion

30 April 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Prevalence of pancreatic steatosis determined by fat quantitation on MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov